Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pasithea Therapeutics Corp (NQ: KTTA )

0.9301 +0.0506 (+5.75%)
Streaming Delayed Price Updated: 1:02 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200,089
Open 0.8600
Bid (Size) 0.9300 (100)
Ask (Size) 0.9499 (1)
Prev. Close 0.8795
Today's Range 0.8519 - 0.9304
52wk Range 0.8601 - 8.200
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 123 stocks made new 52-week lows. 
Via Benzinga
PsychedelicNewsBreaks – Pasithea Therapeutics Corp.’s (NASDAQ: KTTA) CEO Featured in Forbes Article
Via Investor Brand Network

Performance

YTD
-48.04%
-48.04%
1 Month
-24.38%
-24.38%
3 Month
-23.13%
-23.13%
6 Month
-62.19%
-62.19%
1 Year
-73.87%
-73.87%

More News

Read More
Pasithea Biotech Reports That It's Aiming To Be At The Forefront Of The Mental Health Revolution
Via Benzinga
Virtual Reality Technologies Are Reportedly Unlocking New Possibilities For Mental Healthcare
Via Benzinga
Pasithea Reveals Cash Position Of $52.9 Million In Latest Earnings Report, To Expand Pipeline And Fund Operations Well Into 2024
Via Benzinga
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Pasithea Partners With Glimpse Group To Co-Develop VR Environments For Patients With Psychiatric Disorders
Via Benzinga
Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions
Via FinancialNewsMedia
Topics Economy
Exposures Economy
EXCLUSIVE: Glimpse-Pasithea To Co-Develop VR Environments For Patients With Psychiatric Disorders
Via Benzinga
This Company Reports Using Ketamine To Treat Mental Health Disorders
Via Benzinga
Pasithea To Open 3 New Clinics In The U.K. For Patients with Mental Health Issues, Each Clinic Expected To Add ~$5 Million In Annual Revenue
Via Benzinga
Pasithea Therapeutics Announces Plans To Open Three New Clinics In The UK By Mid-2022
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally
Via FinancialNewsMedia
Exposures COVID-19
Global Multiple Sclerosis Drugs Market Expected to Reach $41.99 Billion in 2028
Via FinancialNewsMedia
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
EXCLUSIVE: Pasithea Therapeutics Starts New Multiple Sclerosis Vaccine Development Program
Via Benzinga
From Mobile Clinics to Drug Development, This Company Is Attempting to Tackle Brain Disorders and Promote Mental Health Advances
Via Benzinga
Mobile Clinics for Mental Health Treatments Reportedly Launching in Major Cities Across the U.S.
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
51 Biggest Movers From Yesterday
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; News Corp To Buy Base Chemicals
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
54 Biggest Movers From Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.